129 related articles for article (PubMed ID: 28278076)
1. Adenovirus-based strategies enhance antitumor capability through p53-mediated downregulation of MGMT in uveal melanoma.
Li X; Yuan L; Zhao J; Yang H; Yang Y; Zhang Y; Cun B
Cancer Biol Ther; 2017 Mar; 18(3):194-199. PubMed ID: 28278076
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitination and degradation of MGMT by TRIM72 increases the sensitivity of uveal melanoma cells to Dacarbazine treatment.
Li X; Yang C; Luo N; Yang Y; Guo Y; Chen P; Cun B
Cancer Biomark; 2022; 34(2):275-284. PubMed ID: 34958003
[TBL] [Abstract][Full Text] [Related]
3. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
Cun B; Song X; Jia R; Zhao X; Wang H; Ge S; Fan X
Cancer Biol Ther; 2012 Jan; 13(2):77-84. PubMed ID: 22336909
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Jiang G; Sun C; Li RH; Wei ZP; Zheng JN; Liu YQ
J Cancer Res Clin Oncol; 2015 Jan; 141(1):75-85. PubMed ID: 25103017
[TBL] [Abstract][Full Text] [Related]
5. Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.
Voelter V; Diserens AC; Moulin A; Nagel G; Yan P; Migliavacca E; Rimoldi D; Hamou MF; Kaina B; Leyvraz S; Hegi ME
Int J Cancer; 2008 Sep; 123(5):1215-8. PubMed ID: 18546261
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
7. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
8. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Busch C; Geisler J; Lillehaug JR; Lønning PE
Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
[TBL] [Abstract][Full Text] [Related]
9. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O
Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668
[TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.
Improta G; Ritter C; Pettinato A; Vasta V; Schrama D; Fraggetta F; Becker JC
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1489-1497. PubMed ID: 28405827
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells.
Yang Z; Wei D; Liu F; Liu J; Wu X; Stevens MFG; Bradshaw TD; Luo Y; Zhang J
J Cell Biochem; 2018 Jul; 119(7):5350-5358. PubMed ID: 29331023
[TBL] [Abstract][Full Text] [Related]
12. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
13. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
14. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Jiang G; Jiang AJ; Cheng Q; Tian H; Li LT; Zheng JN
Tumour Biol; 2013 Apr; 34(2):1263-71. PubMed ID: 23430584
[TBL] [Abstract][Full Text] [Related]
15. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
Huang X; Jia R; Zhao X; Liu B; Wang H; Wang J; Zhou Y; Cun B; Ge S; Fan X
Br J Ophthalmol; 2012 Oct; 96(10):1331-8. PubMed ID: 22843987
[TBL] [Abstract][Full Text] [Related]
16. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
17. Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
Göder A; Nagel G; Kraus A; Dörsam B; Seiwert N; Kaina B; Fahrer J
Carcinogenesis; 2015 Aug; 36(8):817-31. PubMed ID: 25998848
[TBL] [Abstract][Full Text] [Related]
18. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
19. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Vlachostergios PJ; Hatzidaki E; Papandreou CN
Neurol Res; 2013 Oct; 35(8):879-82. PubMed ID: 23561593
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Chen YP; Hou XY; Yang CS; Jiang XX; Yang M; Xu XF; Feng SX; Liu YQ; Jiang G
Tumour Biol; 2016 Aug; 37(8):11209-18. PubMed ID: 26943799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
